We use cookies on this website to measure and improve performance. By continuing to browse the site, you are agreeing to our use of cookies.
  • Browse by Category
 
Home » Faculty » Profile
WMC Cancer Faculty
 
WMC Cancer Faculty
 

Dr. Robert C Castellino

Assistant Professor of Pediatrics
Pediatric Hematology/Oncology
2015 Uppergate Drive N.E., Room 426H
United States of America
30322

 
 

Brief Biography:

Duke University; Durham, NC B.S.E. 05/91 Mechanical Engineering Massachusetts Institute of Technology; Cambridge, MA S.M. 06/93 Aeronautics and Astronautics Duke University; Durham, NC M.D. 05/99 Medicine Massachusetts General Hospital; Boston, MA Resident 07/02 Pediatrics Baylor College of Medicine; Houston, TX Fellow 07/05 Pediatric Heme/Onc

 

Academic positions:

* 1999-2000 Instructor in Pediatrics, Massachusetts General Hospital, Boston, MA.
* 2000-2002 Clinical Fellow in Pediatrics, Massachusetts General Hospital, Boston, MA.
* 2002-2005 Clinical Postdoctoral Fellow, Pediatric Heme/Onc, Baylor College of Medicine, Houston, TX.
* 2003-2005 Research Fellow, Pediatric Heme/Onc, Baylor College of Medicine, Houston, TX.
* 2005-2007 Instructor, Pediatric Heme/Onc, Baylor College of Medicine, Houston, TX.
* 2005-2007 Consulting Staff Physician, Department of Pediatrics, Ben Taub General Hospital, Houston, TX.
* 2007-2009 Instructor, Pediatric Heme/Onc, Emory University School of Medicine, Atlanta, GA.
* 2009-present Assistant Professor, Pediatric Heme/Onc, Emory University School of Medicine, Atlanta, GA.
* 2009-present Seminar Director, Cancer Cell Biology Program, Winship Cancer Institute, Emory University. 2011-present Member, Residency Advisory Committee, Dept. of Pediatrics, Emory University.

 

Research interests:

Mechanisms of p53-associated and PI-3 Kinase-associated signaling in medulloblastoma tumorigenesis, metastasis, and treatment responsiveness:
(1) Mechanisms of WIP1-mediated medulloblastoma growth;
(2) Cross-talk between WIP1 and components of Sonic Hedgehog signaling that promotes medulloblastoma growth;
(3) Mechanisms of therapeutic resistance in WIP1 high-expressing medulloblastomas;
(4) Mechanisms of WIP1-mediated medulloblastoma invasion and metastasis;
(5) Mechanisms of medulloblastoma tumorigenesis and progression in the setting of PTEN deficiency; and
(6) Efficacy of pharamacologic inhibition of WIP1 and PI-3 Kinase on growth, invasion, and metastasis of medulloblastoma.

 

What I think of the idea behind WebmedCentral:

I think it is a great idea to incorporate reviews of research both before and after publication into the review process and I would be happy to serve as an Editor.